Skip to main content
construction release_alert
The Scholars Team is working with OIT to resolve some issues with the Scholars search index
cancel
Journal cover image

Novel cancer therapies and their association with diabetes.

Publication ,  Journal Article
Shariff, AI; Syed, S; Shelby, RA; Force, J; Clarke, JM; D'Alessio, D; Corsino, L
Published in: J Mol Endocrinol
February 1, 2019

Over the last decade, there has been a shift in the focus of cancer therapy from conventional cytotoxic drugs to therapies more specifically directed to cancer cells. These novel therapies include immunotherapy, targeted therapy and precision medicine, each developed in great part with a goal of limiting collateral destruction of normal tissues, while enhancing tumor destruction. Although this approach is sound in theory, even new, specific therapies have some undesirable, 'off target effects', in great part due to molecular pathways shared by neoplastic and normal cells. One such undesirable effect is hyperglycemia, which results from either the loss of immune tolerance and autoimmune destruction of pancreatic β-cells or dysregulation of the insulin signaling pathway resulting in insulin resistance. These distinct pathogenic mechanisms lead to clinical presentations similar to type 1 (T1DM) and type 2 (T2DM) diabetes mellitus. Both types of diabetes have been reported in patients across clinical trials, and data on the mechanism(s) for developing hyperglycemia, prevalence, prognosis and effect on cancer mortality is still emerging. With the rapidly expanding list of clinical indications for new cancer therapies, it is essential to understand the impact of their adverse effects. In this review, we focus on hyperglycemia and diabetes related to cancer therapies, describe what is known about mechanism(s) leading to dysregulated glucose metabolism and provide a guide to management of complex oncology patients with a new diagnosis of diabetes.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Mol Endocrinol

DOI

EISSN

1479-6813

Publication Date

February 1, 2019

Volume

62

Issue

2

Start / End Page

R187 / R199

Location

England

Related Subject Headings

  • Neoplasms
  • Insulin Secretion
  • Insulin Resistance
  • Humans
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 2
  • Diabetes Mellitus, Type 1
  • Antineoplastic Agents
  • Animals
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shariff, A. I., Syed, S., Shelby, R. A., Force, J., Clarke, J. M., D’Alessio, D., & Corsino, L. (2019). Novel cancer therapies and their association with diabetes. J Mol Endocrinol, 62(2), R187–R199. https://doi.org/10.1530/JME-18-0002
Shariff, Afreen Idris, Sohail Syed, Rebecca A. Shelby, Jeremy Force, Jeffrey Melson Clarke, David D’Alessio, and Leonor Corsino. “Novel cancer therapies and their association with diabetes.J Mol Endocrinol 62, no. 2 (February 1, 2019): R187–99. https://doi.org/10.1530/JME-18-0002.
Shariff AI, Syed S, Shelby RA, Force J, Clarke JM, D’Alessio D, et al. Novel cancer therapies and their association with diabetes. J Mol Endocrinol. 2019 Feb 1;62(2):R187–99.
Shariff, Afreen Idris, et al. “Novel cancer therapies and their association with diabetes.J Mol Endocrinol, vol. 62, no. 2, Feb. 2019, pp. R187–99. Pubmed, doi:10.1530/JME-18-0002.
Shariff AI, Syed S, Shelby RA, Force J, Clarke JM, D’Alessio D, Corsino L. Novel cancer therapies and their association with diabetes. J Mol Endocrinol. 2019 Feb 1;62(2):R187–R199.
Journal cover image

Published In

J Mol Endocrinol

DOI

EISSN

1479-6813

Publication Date

February 1, 2019

Volume

62

Issue

2

Start / End Page

R187 / R199

Location

England

Related Subject Headings

  • Neoplasms
  • Insulin Secretion
  • Insulin Resistance
  • Humans
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 2
  • Diabetes Mellitus, Type 1
  • Antineoplastic Agents
  • Animals
  • 3202 Clinical sciences